Marcos-Gragera Rafael, Mallone Sandra, Kiemeney Lambertus A, Vilardell Loreto, Malats Núria, Allory Yves, Sant Milena
Epidemiology Unit and Girona Cancer Registry (Oncology Coordination Plan), Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute, Girona, Spain.
National Centre for Epidemiology Surveillance and Health Promotion (CNESPS), National Institute of Health (Istituto Superiore di Sanità), Rome, Italy.
Eur J Cancer. 2015 Oct;51(15):2217-2230. doi: 10.1016/j.ejca.2015.07.028. Epub 2015 Sep 26.
This work presents relative survival estimates regarding urinary tract tumours among adult patients (age⩾15years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000-2007, and on survival time trends from 1999-2001 to 2005-2007.
Data on 677,340 adult urinary tract tumour patients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries. The complete approach was used to estimate survival in 2000-2007; the period approach was used to estimate survival over time.
The age-standardised 5-year relative survival for patients with kidney tumours diagnosed in Europe during 2000-2007 was 60%. The best prognosis was observed in Southern and Central Europe and prognosis improved in all regions along the time period. For invasive and non-invasive patients with bladder tumours combined the age-standardised 5-year relative survival in Europe was 68%. The best prognosis was observed in Southern and Northern Europe. However, in Scotland and The Netherlands the relative survival was significantly lower, although the survival estimates for these two countries were based on invasive tumours only.
Differences in registration practices affect comparisons of survival values between European countries, especially in patients with urinary bladder cancers. The between-country variation in survival is influenced by the varying use of diagnostic investigation in urinary tract tumours. Further data on stage at diagnosis can help to elucidate the influence of diagnostic intensity or early diagnosis on the survival patterns.
本研究呈现了欧洲成年患者(年龄≥15岁)泌尿系统肿瘤的相对生存估计。报告了2000 - 2007年诊断病例的生存估计,以及1999 - 2001年至2005 - 2007年的生存时间趋势。
来自29个欧洲国家的86个基于人群的癌症登记处提供了2000年至2007年期间诊断的677340例成年泌尿系统肿瘤患者的数据(429154例侵袭性和非侵袭性膀胱癌以及248186例侵袭性肾癌)。采用完整方法估计2000 - 2007年的生存率;采用期间方法估计随时间的生存率。
2000 - 2007年在欧洲诊断的肾肿瘤患者的年龄标准化5年相对生存率为60%。在南欧和中欧观察到最佳预后,并且在整个时间段内所有地区的预后都有所改善。对于侵袭性和非侵袭性膀胱癌患者合并计算,欧洲的年龄标准化5年相对生存率为68%。在南欧和北欧观察到最佳预后。然而,在苏格兰和荷兰,相对生存率显著较低,尽管这两个国家的生存估计仅基于侵袭性肿瘤。
登记做法的差异影响欧洲国家之间生存值的比较,尤其是膀胱癌患者。国家间生存差异受泌尿系统肿瘤诊断检查使用差异的影响。关于诊断分期的进一步数据有助于阐明诊断强度或早期诊断对生存模式的影响。